The current biomarkers associated with the efficacy of immunotherapy encompass but are not limited to, PD-L1 expression, MSI status, TMB, Epstein-Barr virus (EBV) infection status, and tumor-infiltrating lymphocytes (TILs). Here, CD274 is linked to neoplasm.